Latest News

  • Illumina, Harvard Pilgrim Partner On Value-Based Contract

    Diagnostics World Brief | Illumina announced today that it has signed a value-based contract with Harvard Pilgrim Health Care with the goal in mind of accelerating wider patient access and reimbursement of next-generation sequencing for non-invasive prenatal testing.

    Feb 1, 2018
  • PerkinElmer, Roche, Charles River, And More: News From January 2018

    Diagnostics World | January featured news, products, and partnerships from around the diagnostics community from numerous companies, universities, and organizations, including PerkinElmer, Roche, Charles River, and more.

    Jan 31, 2018
  • PerkinElmer Launches CE-IVD Assay Kit To Screen New-Borns Affected By DMD

    Diagnostics World Brief | PerkinElmer announced the launch of the first commercially available in-vitro diagnostic kit for newborn screening of Duchenne muscular dystrophy.

    Jan 30, 2018
  • Foundation Medicine, EORTC Announce Collaboration To Facilitate Clinical Trial Enrollment

    Diagnostics World Brief | Foundation Medicine and the European Organisation for Research and Treatment of Cancer announced today a collaboration in which Foundation Medicine’s comprehensive genomic profiling tests will be used to inform patient eligibility for oncology clinical trials through the EORTC’s Screening Patients for Efficient Clinical Trial Access program.

    Jan 30, 2018
  • Illumina Wins $26.7 Million In Patent Fight With Roche Unit Ariosa

    Diagnostics World Brief | Yesterday, Illumina won a $26.7 million jury verdict in a U.S. lawsuit accusing rival Ariosa Diagnostics, a subsidiary of Roche, of using patented prenatal testing technology without authorization.

    Jan 26, 2018
  • Leading Medical Organizations Update Guideline For Molecular Testing, Targeted Therapies In Lung Cancer

    Diagnostics World Brief | Rapid advancements in the molecular diagnostic testing of lung cancer have led to new treatments and greater hope for patients battling lung cancer. To ensure that clinicians stay apace and provide optimal patient care, three leading medical societies have updated their 2013 evidence-based guideline.

    Jan 23, 2018
  • Overhype And PAMA Panic

    Diagnostics World | Experts during a panel session at the 2018 JP Morgan Healthcare Conference weigh in on what in the diagnostics field is overhyped, as well as the implications and expectations of PAMA regulations on innovation and reimbursement.

    Jan 22, 2018
  • CTE In Athletes Linked To Hits To The Head Even Without Concussions

    NPR | Scientists believe they have solid evidence that repeated direct hits to the head can cause the degenerative brain disease seen in some athletes, even if there are no signs of concussion.

    Jan 18, 2018
  • 23andMe’s Ancestry Results “Most Confounding,” New Report Says

    The Mercury News | 23andMe’s spit tests for insights into family history and health were top sellers on Amazon this past holiday season, but its ancestry test and those from three other companies produced drastically different results, a new report said.

    Jan 17, 2018
  • Howard Jacob Leaving HudsonAlpha For AbbVie

    Diagnostics World | Less than three years after leaving the Medical College of Wisconsin for the HudsonAlpha Institute in Huntsville, Alabama, Howard Jacob is starting today as the Vice President of the Genomic Research Center at AbbVie.

    Jan 16, 2018
  • JP Morgan 2018 News Roundup

    Diagnostics World | The 36th annual JP Morgan Healthcare Conference was held this week in San Francisco, bringing together more than 400 companies to showcase their growth and innovation. Here are some of the highlights and announcements we’ve collected from the conference.

    Jan 12, 2018
  • Myriad Receives FDA Approval Of BRACAnalysis CDx As Companion Diagnostic

    Diagnostics World Brief | Myriad Genetics today announced that the FDA approved BRACAnalysis CDx for use as a companion diagnostic by healthcare professionals to identify patients with HER2-negative metastatic breast cancer who have a germline BRCA mutation and are candidates for treatment with the PARP inhibitor Lynparza.

    Jan 12, 2018
  • 10x Genomics, Berry Genomics Partner On NIPT

    Diagnostics World News Brief 10x Genomics and Berry Genomics announced a collaboration today to further develop approaches for next generation noninvasive prenatal testing (NIPT). The parties will collaborate to enable a new service offering for Berry Genomics.

    Jan 8, 2018
  • Mechanism For Resistance To Immunotherapy Treatment Discovered

    Diagnostics World Brief | Dana-Farber researchers say discovery may help identify kidney cancer and melanoma patients that will benefit from checkpoint inhibitor treatment.

    Jan 5, 2018
  • Illumina, KingMed Diagnostics Partner To Develop NGS Technology For Chinese FDA Approval

    Diagnostics World Brief | Illumina and KingMed Diagnostics today announced an agreement to jointly develop novel oncology and hereditary disease testing applications utilizing Illumina's next-generation sequencing technology.

    Jan 4, 2018
  • NYT, Bloomberg Say Apple Is Working On Watch EKG, Noninvasive Glucose

    MobiHealth | Citing anonymous sources within Apple, reports in Bloomberg and the New York Times over the past weeks continue to add to the pile of leaks and rumors about two of Apple's currently under-development health devices: a wrist-worn glucose sensor and an EKG built into the Apple Watch.

    Jan 3, 2018